Banzel FDA Approval History
FDA Approved: Yes (First approved November 14, 2008)
Brand name: Banzel
Generic name: rufinamide
Company: Eisai Medical Research Inc.
Treatment for: Lennox-Gastaut Syndrome
Banzel (rufinamide) is a triazole derivative antiepileptic drug for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome.
Development Timeline for Banzel
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.